TWIST1 Antibody, FITC conjugated

Code CSB-PA025358LC01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) TWIST1 Polyclonal antibody
Uniprot No.
Target Names
TWIST1
Alternative Names
ACS3 antibody; B-HLH DNA binding protein antibody; bHLHa38 antibody; BPES2 antibody; BPES3 antibody; Class A basic helix-loop-helix protein 38 antibody; CRS antibody; CRS1 antibody; CSO antibody; H-twist antibody; OTTHUMP00000116043 antibody; SCS antibody; Twist basic helix loop helix transcription factor 1 antibody; Twist family bHLH transcription factor 1 antibody; Twist homolog 1 (Drosophila) antibody; Twist homolog 1 antibody; TWIST homolog of drosophila antibody; Twist related protein 1 antibody; Twist-related protein 1 antibody; TWIST1 antibody; TWST1_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Twist-related protein 1 protein (1-80AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
FITC
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-ARNTL/BMAL1 heterodimer.
Gene References into Functions
  1. miR-539 inhibited the EMT of TE3 cells by downregulating TWIST1, and TWIST1 was a target of miR-539. PMID: 28653599
  2. Study demonstrated that TWIST protein expression was elevated in liver cancer tissue specimens and was positively correlated with MDR1 expression. Knockdown of TWIST increased the sensitivity of RHepG2 cells to antineoplastic agents through a reduction in MDR1 expression and drug efflux ability. PMID: 30066890
  3. we demonstrate that HMGA2 is correlated with GC VM formation and that positivity for both HMGA2 and VM predicts a worse clinical outcome for GC patients. HMGA2 can directly target Twist1 and promote the expression of Twist1 and VE-cadherin. PMID: 28533522
  4. Study provides evidence that genetic variants in SNAI1 and TWIST1 are associated with breast cancer (BC) and ovarian cancer (OC) susceptibility and suggests a synergistic effect of those related loci on BC/OC risk. PMID: 30272327
  5. As potential molecular markers for bladder carcinoma, both TWIST1 and LASS2 transcripts seem to play role during the tumorigenesis and development of bladder cancer. PMID: 30213291
  6. Authors found that swainsonine inhibits cell invasion and EMT in the esophageal carcinoma cells by downregulation of Twist1 and deactivation of the PI3K/AKT signaling pathway. PMID: 28899457
  7. The administration of si-Twist1 cancelled the effect of miR-203 inhibitor on cell proliferation, apoptosis, invasion, and migration. These demonstrated that miR-203 may function as a tumor-suppressive microRNA in BCa by negatively targeting Twist1. PMID: 28893347
  8. Expression levels of MACC1, CD44, Twist1, and KiSS-1 are related to duration of overall survival among patients with colonic adenocarcinoma. PMID: 30021598
  9. Data identified Twist1 and CD44 as novel REST targeted genes and provide new insight into the epigenetic regulation of Twist1 and CD44 by REST. PMID: 28256535
  10. TWIST1 promotes catabolic reactions by inducing MMP3 expression through 5hmC gain in MMP3 promoter via regulation of TET1. PMID: 28220902
  11. The results support the role of TWIST in carcinogenesis, development of oral squamous cell carcinoma, and its metastasis to lymph nodes. PMID: 30197332
  12. TWIST1-miR-214 pathway in the control of migration and invasion of lung adenocarcinoma. PMID: 29693173
  13. the SDF1/CXCR4 signaling pathway is involved in Lowintensity pulsed ultrasoundpromoted periodontal ligament stem cell migration. PMID: 29620151
  14. Findings suggest that cytoplasmic, rather than nuclear expression of Twist1 can be considered as a prognostic marker especially for patients with clear cell renal cell carcinoma. PMID: 29204790
  15. Chromatin immunoprecipitation (ChIP), quantitative ChIP and dual luciferase activity assays were used to confirm the binding of SOX6 to the promoter region of TWIST1. PMID: 29512775
  16. In cancer patients, elevated levels of Twist1 are associated with greater degrees of muscle wasting. PMID: 29920276
  17. Twist, E-cadherin, and N-cadherin protein were differently expressed in endometrioid adenocarcinoma tissues and in normal endometrium which indicates their potential function for endometrioid adenocarcinoma development. PMID: 29237910
  18. Study shows that molecular dynamic simulations provide a structural explanation for the loss-of-function associated with the Saethre-Chotzen syndrome TWIST1 mutation and provides a proof of concept of the predictive value of these MD simulations; MD simulations highlighted a clear decrease in the stability of the alpha-helix during the dimerization of the mutated R154P TWIST1/E12 dimer compared to the wild-type TE comp... PMID: 28521820
  19. Basic performance testing showed that the combined restriction digital PCR assay enabled detection of 0.14% of the TWIST1 methylation level for the lymphocyte DNA PMID: 28081635
  20. High TWIST expression is associated with hepatocellular carcinoma. PMID: 28677802
  21. Overexpressed TWIST1 can be correlated with upregulation of the cancer stem cell marker OCT4 and the protein may play critical regulatory role in OCT4 gene expression. PMID: 29299035
  22. Study provides evidence that upregulation of the Twist gene promotes EMT molecular events and enhances the metastatic ability of colon tumor cells, while Twist-shRNA effectively silences Twist gene expression in the HCT116 cell line, promoting mesenchymalepithelial transition and effectively inhibiting colon cancer cell migration and invasion. PMID: 29115546
  23. demonstrate that miR-326 served as a tumor suppressor by targeting TWIST1, and may serve as a biomarker or therapeutic target for patients with EC. PMID: 28975990
  24. CRP bound to surface CD32 (also known as FcgammaRII) on myeloma cells, which activated a pathway mediated by the kinase p38 MAPK and the transcription factor Twist that enhanced the cells' secretion of osteolytic cytokines. PMID: 29233917
  25. The findings suggest that AEG-1 promotes gastric cancer metastasis through upregulation of eIF4E-mediated MMP-9 and Twist. PMID: 28661037
  26. The aggresome formation of the Twist1 deletion mutants was confirmed by counterstaining with known aggresome markers: Vimentin, HDAC6, and gamma tubulin and further validated by MG-132 treatment. In addition, it was found that the aggresomes generated by the Twist1Delta30-46 construct are more stable than the aggresome produced by the Twist1Delta47-100 construct as well as the wild-type Twist1 protein. PMID: 28779345
  27. These studies identified harmine as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven non-small cell lung cancer (NSCLC)including EGFR mutant, KRAS mutant and MET altered NSCLC PMID: 28851812
  28. Data indicate a mechanism in breast cancer cells that tripartite motif-containing 28 protein (TRIM28) enhances metastasis by stabilizing TWIST1, suggesting that targeting TRIM28 could be an efficacious strategy in breast cancer treatment. PMID: 27412325
  29. Twist1 and Snail1 expression levels were associated with lymphovascular space invasion, lymph node metastasis and histological grade in cervical squamous cell carcinoma. PMID: 29101499
  30. gene TWIST1 showed no significant difference in expression between groups PMID: 28843749
  31. the inhibition of Twist1 transfected with siRNA could enhance the irinotecan sensitivity in LoVo/CPT-11R cells and downregulate the expression of vimentin and CD44. Our data provide evidence that EMT and CSC-like phenotype induced by Twist1 contribute to acquire resistance to irinotecan and enhanced migration and invasion in colon cancer PMID: 28627611
  32. TWIST1, in part via GAS6 and L1CAM, led to higher expression and activation of Akt upon cisplatin treatment, and inhibition of Akt activation sensitized cells to cisplatin. PMID: 27876874
  33. study has further confirmed that TWIST is a prognostic marker in prostate cancer, identified its potential downstream targets and genes that could possibly give additional prognostic value to predict TWIST-mediated prostate cancer progression PMID: 28120266
  34. High Twist-1 expression, aberrant E-cadherin and high EZH2 expression in primary prostate cancer are considered as adverse prognostic markers of an aggressive tumor with high metastatic potential. PMID: 28832071
  35. ADAM12 is induced by Twist1 and plays a crucial role in tumor invasion and metastasis by regulating both invadopodia and focal adhesions PMID: 28468988
  36. Taken together, these findings demonstrated that Twist was upregulated in high invasion and metastasis cell lines as well as invasive ductal carcinoma (IDC) tissues companioned with downregulated expression of E-cadherin and ER, which provides important clues for the deeper study of breast cancer PMID: 28901319
  37. The mechanism study revealed that ASLNC02525, as an RNA sponge, broke the negative regulation of twist1 by hsa-miRNA-489-3p, and once ASLNC02525 was silenced, the highly expressed hsa-miRNA489-3p regained its regulation on twist1 and inhibited the proliferation and invasion. PMID: 28713968
  38. the results from the present study indicate that BaP enhances the epithelial-mesenchymal transition-associated migration of lung adenocarcinoma A549 cells by upregulating Twist1. PMID: 28791412
  39. MMP9 and TWIST1 were identified as more valuable biological targets for the early diagnosis and targeted therapy of lung cancer through Kaplan-Meier analysis of TCGA lung adenocarcinoma datasets. PMID: 29443542
  40. HIF-2alpha and VM were overexpressed in pancreatic cancer tissues and were associated with poor pathological characteristics. HIF-2alpha contributes to VM formation by regulating the expression of VE-cadherin through the binding of the transcription factor Twist1 to the promoter of VE-cadherin in pancreatic cancer both in vitro and in vivo. PMID: 28599281
  41. Twist1 was demonstrated to act as a direct target of miR300, and was negatively regulated by miR300. In addition, miR300 overexpression downregulated the expression of the primary factors involved in the NFkappaB signaling pathway. PMID: 28765882
  42. TWIST expression was dramatically decreased in both spontaneous abortion and recurrent pregnancy loss. TWIST may have a functional role in decidualization of endometrial cells and syncytialization of cytotrophoblast cells. PMID: 28337825
  43. PVT1 promotes prostate cancer invasion and metastasis by modulating endothelial-mesenchymal transition. Furthermore, PVT1 can promote EMT by up-regulation of Twist1, a transcription factor associated with EMT. We then confirmed that PVT1 acts as a sponge for miRNA-186-5p and positively regulates Twist1 by a sponge effect. PMID: 29452232
  44. lncRNA CHRF-induced miR-489 loss facilitates metastasis and EMT process of CRC cells probably via TWIST1/EMT signaling pathway. PMID: 28430582
  45. TAMs [tumor-associated macrophages] distribution suggested antitumor activity and the potential for tumor metastasis was only partly due to Twist-mediated epithelial-mesenchymal transition. PMID: 29063902
  46. Tumor cell hypoxia induced Bcl-2/Twist1 complex formation, promoting tumor cell invasion in oral squamous cell carcinoma. PMID: 28032603
  47. Addition of a TWIST1/NID2-based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology. PMID: 28106542
  48. Data show that TUSC2 is a direct target of miR-584, which is transcriptionally regulated by TWIST1. PMID: 27661106
  49. Twist1 could promote the accumulation of DNA damage repair and inhibit the apoptosis of nasopharyngeal carcinoma cells, promoting radioresistance. PMID: 27793033
  50. The mutual correlation between the expression level of TWIST1 and ID1 might be a critical factor driving the process of the human odontoblasts' differentiation. PMID: 29159326

Show More

Hide All

Involvement in disease
Saethre-Chotzen syndrome (SCS); Robinow-Sorauf syndrome (RSS); Craniosynostosis 1 (CRS1)
Subcellular Location
Nucleus.
Tissue Specificity
Subset of mesodermal cells.
Database Links

HGNC: 12428

OMIM: 101400

KEGG: hsa:7291

STRING: 9606.ENSP00000242261

UniGene: Hs.644998

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*